| 冯湘然,高永凤,蓝孝斐,等.激素无效性免疫检查点抑制剂相关肺炎的诊疗进展[J].中国肿瘤,2025,34(3):244-250. |
| 激素无效性免疫检查点抑制剂相关肺炎的诊疗进展 |
| Progress in the Diagnosis and Treatment of Steroid-Unresponsive Pneumonitis Related to Immune Checkpoint Inhibitors |
| 投稿时间：2024-10-28 |
| DOI：10.11735/j.issn.1004-0242.2025.03.A012 |
|
 |
| 中文关键词: 免疫检查点抑制剂相关肺炎 糖皮质激素 免疫抑制剂 抗纤维化治疗 免疫再挑战 |
| 英文关键词:immune checkpoint inhibitor-related pneumonitis glucocorticoids immunosuppressant anti-fibrotic therapy immune re-challenge |
| 基金项目:国家自然科学基金项目（81672271）；上海市呼吸传染病应急防控与诊治重点实验室项目（20dz2261100）；上海市重点专科项目（shsiczdzk02202）；上海市重大传染病研究基地培育项目（20dz2210500）；上海交通大学医学院高水平地方高校创新团队（SSMU-ZDCX20181001） |
|
| 摘要点击次数: 156 |
| 全文下载次数: 40 |
| 中文摘要: |
| 摘 要：免疫检查点抑制剂相关肺炎（immune checkpoint inhibitor-related pneumonitis，CIP）是一种常见的免疫相关不良反应。目前CIP的治疗主要依赖于糖皮质激素，70%~ 80%的患者可通过常规糖皮质激素治疗得到控制，但激素无效性CIP常常症状严重甚至危及生命。对于激素无效性CIP，尚无标准治疗方案，临床未满足需求较大。全文对激素无效性CIP的诊疗进展和探索性研究进行综述，以期为临床诊疗实践提供循证依据。 |
| 英文摘要: |
| Abstract： Immune checkpoint inhibitor-related pneumonitis (CIP) is a relatively common immune-related adverse event. The current treatment for CIP mainly relies on glucocorticoids，with 70%~80% of patients being controlled by conventional glucocorticoid therapy. However，steroid-unresponsive CIP is often severe and can be life-threatening. There is no standard treatment protocol for steroid-unresponsive CIP， highlighting a significant unmet clinical need. This paper reviews the diagnosis，treatment progress， and exploratory research of steroid-unresponsive CIP to provide evidence-based guidelines and directions for clinical and translational research. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |